Pathogenetic and Clinical Features of Comorbid Conditions in Gout

Mualliflar

  • Nigora Khasanovna Tukhtaeva Tashkent State Medical University, Uzbekistan Muallif
  • Kobil Khakimovich Khasanov Chirchik Branch of Tashkent State Medical University, Uzbekistan Muallif
  • Irodakhon Ilyaskhanovna Kodirova Tashkent State Medical University, Uzbekistan Muallif

Kalit so‘zlar:

Drug therapy, gout, hyperuricemia, metabolic diseases, uric acid

Abstrak

Gout is the most common inflammatory arthritis worldwide and represents a growing global health problem. It develops as a result of hyperuricemia caused by impaired purine metabolism, leading to the deposition of monosodium urate (MSU) crystals and recurrent inflammatory arthritis. Although hyperuricemia is the primary risk factor, genetic predisposition, impaired urate transport, and emerging factors such as the gut microbiota also contribute to disease development. Acute flares are mediated by activation of the NLRP3 inflammasome induced by MSU crystals and the subsequent production of interleukin-1β, whereas chronic inflammation leads to the formation of tophi and structural joint damage. Gout is closely associated with metabolic syndrome, chronic kidney disease, and cardiovascular diseases, which contribute to persistently elevated mortality. Although advances in imaging and pharmacological therapy have improved diagnosis and management, the real-world application of urate-lowering therapy remains suboptimal. Further research and continuous efforts by healthcare professionals are needed to improve long-term disease control.

NINE muqovasi

Yuklab olishlar

Nashr qilingan

2026-11-02

Nashr

Jild 3 Nomeri 11 (2026): 2026-yil, Noyabr

Bo'lim

Articles

Litsenziya

Mualliflik huquqi (c) 2026 The author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Pathogenetic and Clinical Features of Comorbid Conditions in Gout. (2026). New Innovations in National Education, 3(11). https://reandpub.uz/nine/article/view/1364

Foydalanilgan adabiyotlar

Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020;16:380–90.

Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des 2019;25:700–9.

McCormick N, Lin K, Yokose C, Lu N, Zhang Y, Choi HK. Unclosing premature mortality gap among patients with gout in the US general population, independent of serum urate and atherosclerotic cardiovascular risk factors. Arthritis Care Res (Hoboken) 2024;76:691–702.

Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum 2020;50:S11–6.

Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010;68:199–203.

Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther 2024;9:212.

Punjwani S, Jani C, Liu W, Kakoullis L, Salciccioli I, Al Omari O, et al. Burden of gout among different WHO regions, 1990-2019: estimates from the global burden of disease study. Sci Rep 2024;14:15953.

Yokose C, McCormick N, Lu N, Tanikella S, Lin K, Joshi AD, et al. Trends in prevalence of gout among US Asian adults, 2011-2018. JAMA Netw Open 2023;6:e239501.

Ahn JK. Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. J Rheum Dis 2023;30:88–98.

Health Insurance Review & Assessment Service. Medical care expenditure statistical indicators for the first half of 2023 [Internet]. Health Insurance Review & Assessment Service.

Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol 2018;37:2529–38.

Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis 2018;77:1048–52.

Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012;8:610–21.

Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber G, Vollenweider P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One 2012;7:e39321.

Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang Y. Population impact attributable to modifiable risk factors for hyperuricemia. Arthritis Rheumatol 2020;72:157–65.

Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol 2014;66:185–96.

Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ 2018;363:k3951.

Tin A, Marten J, Halperin Kuhns VL, Li Y, Wuttke M, Kirsten H, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet 2019;51:1459–74.

Major TJ, Takei R, Matsuo H, Leask MP, Sumpter NA, Topless RK, et al. A genome-wide association analysis reveals new pathogenic pathways in gout. Nat Genet 2024;56:2392–406.

Park YE, Kim JH. Revolutionizing gut health: exploring the role of gut microbiota and the potential of microbiome-based therapies in lower gastrointestinal diseases. Kosin Med J 2023;38:98–106.

Xing SC, Meng DM, Chen Y, Jiang G, Liu XS, Li N, et al. Study on the diversity of Bacteroides and Clostridium in patients with primary gout. Cell Biochem Biophys 2015;71:707–15.

Mendez-Salazar EO, Vazquez-Mellado J, Casimiro-Soriguer CS, Dopazo J, Cubuk C, Zamudio-Cuevas Y, et al. Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism. Mol Med 2021;27:50.

Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol 2015;77:323–45.

Ahn EY, So MW. The pathogenesis of gout. J Rheum Dis 2025;32:8–16.

Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009;183:787–91.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–41.

Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet 2021;397:1843–55.

Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009;68:1290–5.

Dalbeth N, Smith T, Nicolson B, Clark B, Callon K, Naot D, et al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum 2008;58:1854–65.

Chhana A, Callon KE, Pool B, Naot D, Watson M, Gamble GD, et al. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis 2011;70:1684–91.

Yoo HG, Lee SI, Chae HJ, Park SJ, Lee YC, Yoo WH. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int 2011;31:485–91.

Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012;125:679–87.

Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 2017;15:123.

Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012;2:e000282.

Goncalves DL, Moreira TR, da Silva LS. A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease. Sci Rep 2022;12:6251.

Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 2018;72:798–810.

Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 2020;382:2504–13.

Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, et al. Preventing early renal loss in diabetes (PERL) study: a randomized double-blinded trial of allopurinol-rationale, design, and baseline data. Diabetes Care 2019;42:1454–63.

Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens 2008;26:2085–92.

Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739–42.

Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014;26:186–91.

Rho YH, Lu N, Peloquin CE, Man A, Zhu Y, Zhang Y, et al. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Ann Rheum Dis 2016;75:91–5.

Pascart T, Ramon A, Ottaviani S, Legrand J, Ducoulombier V, Houvenagel E, et al. Association of specific comorbidities with monosodium urate crystal deposition in urate-lowering therapy-naive gout patients: a cross-sectional dual-energy computed tomography study. J Clin Med 2020;9:1295.

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020;72:744–60.

AGEPHA Pharma. U.S. FDA approves first anti-inflammatory drug for cardiovascular disease [Internet]. AGEPHA Pharma; 2023 [cited 2026 Mar 16].

Nidorf SM, Fiolet AT, Mosterd A, Eikelboom JW, Schut A, Opstal TS, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47.

Nurmetov, Kh. T., Marufkhanov, Kh. M., Talipov, R. M., & Tukhtaeva, N. Kh. (2023). Klinikoepidemiologicheskie osobennosti ankiloziruyushchego spondilartrita v usloviyakh statsionar. (in Russian)

Tukhtaeva, N. K. (2023). The degree of damage to the gastroduodenal zone in patients with rheumatoid arthritis against the background of basic and anti-inflammatory therapy. Texas Journal of Medical Science, 25, 58-62.

Kh, T. N., Sh, K. M., & Kurbanov, A. K. (2021). Assessment of the gastrointestinal tract in patients with rheumatoid arthritis. European Journal of Pharmaceutical and Medical Research, 2(5), 34-37.

Tukhtaeva, N. Kh., & Khasanova, G. Kh. (2023). ROL KHONDROITINA SULFATA V LECHENII DEFORMIRUYUSHCHEGO OSTEOARTROZA. (in Russian)

Nurmetoa, Kh. T., Marufkhanov, Kh. M., Talipov, R. M., & Tukhtaeva, N. Kh. (2023). Clinical and Epidemiological Features of Ankylosing Spondylarthritis in A Hospital Setting.